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AbsTRACT
Objective To investigate whether mentioning free or 
lower cost smoking cessation medication as a trigger for 
thinking about quitting is related to higher medication use, 
more quit attempts and quit success, and whether these 
associations are modified by education and income.
Methods Data were derived from the 2013 and 
2014 surveys of the International Tobacco Control 
Netherlands (n=1164) and UK (n=768) cohort. Logistic 
regression analyses were used to assess associations 
between mentioning in 2013 that free/lower cost 
smoking cessation medication was a trigger for thinking 
about quitting smoking and the use of medication, quit 
attempts and smoking cessation in 2014.
Results 37.0% of smokers in the UK and 24.9% of 
smokers in the Netherlands mentioned free/lower cost 
medication as a trigger for thinking about quitting. Smokers 
who mentioned this trigger were more likely to have used 
cessation medication during a quit attempt both in the UK 
(OR=4.19, p<0.001) and in the Netherlands (OR=2.14, 
p=0.033). The association between mentioning free/lower 
cost medication as a trigger for thinking about quitting and 
actual quit attempts was significant in the UK (OR=1.45, 
p=0.030), but not in the Netherlands (OR=1.10, p=0.587). 
There was no significant association with quit success. 
Associations did not differ across income and education 
groups.
Conclusion Free/lower cost smoking cessation 
medication may increase the use of cessation medication 
and stimulate quit attempts among smokers with low, 
moderate and high education and income.
InTROduCTIOn
In Western countries, the proportion of smokers 
is not equally divided among low and high socio-
economic groups.1–3 Individuals with lower educa-
tion and income are more likely to smoke and 
smoke more cigarettes a day than higher educated 
and more affluent people.4 5 This disparity causes 
smoking to be the largest contributor to socioeco-
nomic differences in health and mortality observed 
in Western countries.6 7 Although the proportion of 
people who smoke is generally declining, inequali-
ties according to socioeconomic status (SES) have 
sustained or increased over time.2 3 8–11 In the UK, 
21% of individuals with no formal qualifications 
smoke compared with 9% of individuals with a 
degree.12 In the Netherlands (NL), a comparable 
SES gap in smoking prevalence exists: 28% of 
lower educated adults smoke compared with 19% 
of higher educated adults.13 In order to reduce this 
socioeconomic gap, it is vital to develop methods 
and policies effective for smokers with a lower SES.
Having to pay for smoking cessation treatment 
like bupropion, varenicline or nicotine replacement 
therapy—from hereon referred to as ‘cessation 
medication’—can be a barrier for seeking treatment, 
particularly for people on a low income.14 More 
smokers use cessation medication when it is cost-
free,15 and this can substantially increase the number 
of long-term quitters.16 In a study based on data from 
the International Tobacco Control (ITC) Europe 
surveys, respondents with lower education and 
income mentioned the availability of free/lower cost 
medication more often as a trigger for thinking about 
quitting smoking than other education and income 
groups.17 Still, mentioning free/lower cost medica-
tion as a trigger for thinking about quitting does not 
necessarily lead to more use of medication, nor to 
more quit attempts and a greater likelihood of quit 
success. Data from the ITC Four Country surveys18 
suggested that mentioning free/lower cost medica-
tion as a trigger to think about quitting was positively 
associated with making a quit attempt. Yet, it was not 
examined whether this association was dependent on 
respondents’ income or education. Furthermore, it 
was not assessed whether free/lower cost medication 
as a trigger was associated with actual use of cessation 
medication and quit success.
In the current study, the ITC data from the UK 
and the NL are used to investigate SES differences in 
mentioning free/lower cost medication as a trigger to 
think about quitting smoking and quitting behaviour. 
The cultural and economic similarities of the UK and 
the NL make it interesting to compare these two coun-
tries. In both countries, smokers have the opportunity 
to receive free/lower cost smoking cessation treat-
ment. In the UK, the National Health Service provides 
smokers with free or subsidised cessation medication 
(dependent on smokers’ income) by trained practi-
tioners in routine practice and via the stop-smoking 
services; behavioural support can also be obtained free 
via the stop-smoking services for all.19 20 Stop-smoking 
services vary across the UK but the standard model of 
treatment is an assessment before quitting which takes 
place about a week later, and then weekly sessions 
until 4 weeks after the quit date.21 In the NL, pharma-
cotherapy can be reimbursed once every year by the 
Dutch health insurance system only in combination 
with behavioural therapy, irrespective of treatment 
completion or outcome. There are possibilities for 
receiving behavioural therapy, such as the general prac-
titioner, outpatient services or independent healthcare 
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providers registered in the Dutch quality register for scientifically 
proven effective smoking cessation treatment. Still, reimbursement 
applies only after patients have spent a mandatory deductible for 
general healthcare costs (at least €350 in 2013).
The aim of this study is to investigate whether in the UK and 
the NL free/lower cost cessation medication mentioned as a trigger 
for thinking about quitting is related to use of medication, quit 
attempts and quit success and whether these associations are modi-
fied by education and income. It is hypothesised that smokers who 
mentioned free or lower cost medication as a trigger were more 
likely to make a quit attempt, to use cessation medication and had 
higher quit rates. Moreover, it is expected that this association 
is stronger for smokers with lower income and education than 
smokers with higher income and education, as the cost of cessation 
treatment has been mentioned as a barrier to quitting smoking by 
smokers with lower income and education.22 23
MeThOds
Data were used from the 2013 and 2014 surveys of the ITC 
NL and UK cohorts. The ITC Project is a prospective cohort 
study of a representative sample of smokers and ex-smokers in 
each country.24 Survey data were collected by web (59%) and 
telephone (41%) for the UK and by web only for the NL. Surveys 
were collected from February to September 2013 and from 
August to December 2014 in the UK, and from May to June 
2013 and from May to June 2014 in the NL. All respondents 
were current smokers at time of enrolment. More details on the 
methods of the ITC data collection can be found in previous 
publications.24 25 Dropout between the two survey waves was 
18% for the NL and 30% for the UK. In the current study, 
participants were selected of 18 years and older who partici-
pated in both waves and who smoked at least monthly in the 
2013 survey. This formed a sample of n=1164 smokers from the 
NL, and n=768 from the UK.
Free/lower cost medication as a trigger for thinking about 
quitting
The main independent variable of this study was whether respon-
dents mentioned free/lower cost smoking cessation medication 
as a trigger for thinking about quitting. This is referred to as 
‘free/lower cost medication as a trigger’ in the remainder of this 
paper. It was measured in the 2013 surveys with the following 
question: ‘In the past 6 months, has free, or lower cost, stop-
smoking medication led you to think about quitting?’.17
The question was part of a list with four policy triggers, of 
which each could be selected independently from the others by 
the respondent. The other triggers (which were not the focus in 
this paper) were: the price of cigarettes, smoking restrictions in 
public places and warning labels on cigarette packages. Response 
options were: ‘not at all’, ‘somewhat’ and ‘very much’. For the 
analyses, the response options were dichotomised: ‘not at all’ 
was classified as no trigger for thinking about quitting; ‘some-
what’ and ‘very much’ were classified as a positive trigger for 
thinking about quitting smoking.
use of smoking cessation medication
Participants in both countries were asked in the 2014 surveys 
whether they had previously used smoking cessation medica-
tions. In the NL, respondents were asked about medication use 
in the last year while in the UK, medication use during the last 
quit attempt was assessed. Therefore, these survey items were 
not entirely comparable.
Quit attempts and quit success
To measure quit attempts, participants were asked the following 
question in the 2014 survey: ‘Have you made any attempts 
(successful or not) to stop smoking in the last year?’ Participants 
who responded affirmatively on this question were defined as 
having made a quit attempt. Successful quitters were defined as 
current smokers in 2013 who reported having made a quit attempt 
and not smoking at all or less than once a month in 2014.26
Income and education
Respondents from the NL were asked about their monthly gross 
household income while UK respondents reported their annual 
gross household income. Response categories also differed 
between the two countries. The income variables were recoded 
into three categories based on tertiles in each country: defined 
as ‘low’ if income <€2000 (NL) or <£15 000 (UK), ‘moderate’ 
if between €2000 and €3000 (NL) or between £15 000 and 
£30 000 (UK), and ‘high’ if >€3000 (NL) or >£30 000 (UK). 
Respondents had the option not to disclose their income. These 
responses were treated as missing values. The level of educa-
tion for both countries was recoded into three groups: ‘low’ for 
none completed, elementary school and lower secondary educa-
tion; ‘moderate’ for secondary vocational education and middle 
secondary education; and ‘high’ for upper secondary education, 
university and postgraduate.
Covariates
Several covariates were used in the analyses, including gender and 
age (divided into four categories: 18–24 years, 25–39 years, 40–54 
years, and 55 years and older). Nicotine dependence was measured 
by the Heaviness of Smoking Index (HSI).27 28 The HSI is a score 
ranging from 0 to 6 (low to high nicotine dependence) and is calcu-
lated based on both the number of cigarettes smoked per day and 
the time before smoking the first cigarette after waking up.
Analyses
IBM SPSS V.21.029 was used to analyse the data. Cross-sectional 
and longitudinal weights were calculated using age and gender 
for each country separately.24 Three multivariate logistic regres-
sion analyses were used to analyse the data. The associations 
were assessed between mentioning free/lower cost medication 
as a trigger to quit and (1) use of smoking cessation medica-
tion, (2) making a quit attempt and (3) smoking cessation 1 year 
later. Covariates in all analyses were gender, age and HSI. To 
account for possible ‘time-in-sample’ effects where answers from 
respondents who have participated in multiple survey waves 
vary from newly recruited respondents,30 analyses were adjusted 
for the respondents’ number of times they participated in the 
survey.31 Two-way interactions between education and trigger 
and between income and trigger were included in the anal-
yses. Due to between-country differences in data collection and 
survey items, analyses were conducted separately for the NL and 
the UK. As secondary analyses, the other three policy triggers 
(the price of cigarettes, smoking restrictions in public places and 
warning labels on cigarette packages) were added as independent 
variables in separate multivariate logistic regression analyses.
ResulTs
demographics
The sociodemographic characteristics of the respondents are 
presented in table 1. The UK research sample had a higher 
percentage (53%) of high educated smokers than the NL (25%) 
(p<0.001). In the NL, 30% of respondents did not report their 
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household income, compared with 8% in the UK. Online supple-
mentary appendix 1 shows medication use, quit attempts and 
quit success for respondents who did and who did not disclose 
their income. Smokers in both countries had a comparable level 
of nicotine dependence (p=0.448), with the largest group of 
respondents reporting an HSI between 2 and 4. Loss to follow-up 
was higher among younger participants in both countries and 
higher among lighter smokers in the UK (online supplementary 
appendix 2).
Free/lower cost medication as a trigger for thinking about 
quitting
In 2013, free/lower cost medication was mentioned as a trigger 
for thinking about quitting by 24.9% of the respondents in 
the NL and 37.0% of the respondents in the UK (results not 
shown in table). When comparing income groups, free/lower 
cost medication as a trigger was mentioned in the NL by 30.7% 
of low-income smokers compared with 20.9% of moderate-in-
come smokers and 21.1% of high-income smokers (χ2 (2)=9.45, 
p=0.009). In the UK, free/lower cost medication as a trigger 
was mentioned by 40.2%, 33.6% and 39.2% of low, moderate 
and high-income groups, respectively (χ2 (2)=2.47, p=0.290). 
When education groups were compared, in the NL 28.8% of 
smokers with low education, 25.7% of smokers with moderate 
education and 21.2% of smokers with high education mentioned 
free/lower cost medication as a trigger (χ2 (2)=4.98, p=0.083). 
In the UK, 38.8% of smokers with low education, 41.1% of 
smokers with moderate education and 34.1% of smokers with 
high education mentioned free/lower cost medication as a trigger 
(χ2 (2)=3.17, p=0.205).
Medication use
In the NL, 31.2% of smokers who made a quit attempt in the last 
year and mentioned free/lower cost medication as a trigger used 
smoking cessation medication in the last year compared with 
15.8% who did not report this trigger (p=0.001, figure 1 and 
Table 1 Characteristics of participants in the first wave in the UK 
and the Netherlands (2013). Weighted data
uK
The 
netherlands between-country 
differences(n=768) (n=1164)
Gender
  Female (%) 48.6 49.3 χ2(1)=0.08
P=(0.777)
Age
  18–24 years (%) 11.9 12.8 χ2(3)=4.90
  25–39 years (%) 27.2 23.1 (P=0.179)
  40–54 years (%) 33.4 33.4
  55 years and older (%) 27.6 30.6
Heaviness of Smoking Index
  0–1 (%) 27.5 29.6 χ2(2)=1.61
  2–4 (%) 65.8 63 (P=0.448)
  5–6 (%) 6.7 7.5
Income level
  Low (%) 28.5 22 χ2(2)=144.40
  Moderate (%) 31.7 20.1 (P<0.001)
  High (%) 32 27.8
  Not reported (%) 7.7 30.1
Educational level
  Low (%) 17.4 29.2 χ2(2)=146.59
  Moderate (%) 30.1 45.4 (P<0.001)
  High (%) 52.5 25.4
Figure 1 Medication use, quit attempts and successful quitters among smokers who mentioned and smokers who did not mention free/lower cost 
medication as a trigger to think about quitting smoking in the Netherlands. *The denominator is all participants who made a quit attempt in the last 
year. **The denominator is all smokers.
Table 2 Medication use, quit attempts and quit success within the 
entire sample and within respondents who mentioned free/lower cost 
medication as a trigger (weighted data)
entire sample
Mentioned free/lower cost 
medication as a trigger
uK nl P values uK nl P values
Medication use (%) 39.8 20.1 <0.001 54.8 31.2 <0.001
Quit attempts (%) 43 32.7 <0.001 48.2 36.2 0.003
Quit success (%) 35.2 28.5 0.064 34.1 19.3 0.014
NL, Netherlands.
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table 2). In the UK, the medication use in the group of respon-
dents that mentioned free/lower cost medication as a trigger was 
54.8% compared with 29.2% in the group that did not report 
the trigger (p<0.001, figure 2). Free/lower cost medication as a 
trigger was also positively associated with medication use in multi-
variate analyses both in the UK (OR=4.19, p<0.001) and in the 
NL (OR=2.14, p=0.033) (table 3). The multivariate analyses 
showed no significant interactions between free/lower cost medi-
cation as a trigger, medication use and education and income 
groups. With the other policy triggers (smoking restrictions in 
public places, the price of cigarettes and warning labels on ciga-
rette packages) added to the model, free/lower cost medication as 
Figure 2 Medication use, quit attempts and successful quitters among smokers who mentioned and smokers who did not mention free/lower cost 
medication as a trigger to think about quitting smoking in the UK. *The denominator is all participants who made a quit attempt in the last year. 
**The denominator is all smokers.
Table 3 Multivariate logistic regression analyses† showing associations between free/lower cost cessation medication as a trigger for thinking 
about quitting smoking and medication use, quit attempts and quit success in the UK and the Netherlands (weighted data)
Medication use† Quit attempts Quit success†
OR (95% CI) OR (95% CI) OR (95% CI)
uK nl uK nl uK nl
Gender
  Female 0.67 (0.38 to 1.19) 0.70 (0.36 to 1.35) 1.04 (0.75 to 1.44) 0.79 (0.59 to 1.07) 1.28 (0.74 to 2.20) 1.95 (1.10 to 3.45)*
  Male 1 1 1 1 1 1
Age (years)
  18–24 1.67 (0.61 to 4.58) 0.14 (0.03 to 0.71)* 2.34 (1.33 to 4.13)** 1.18 (0.71 to 1.97) 0.60 (0.23 to 1.54) 0.33 (0.10 to 1.06)
  25–39 0.97 (0.42 to 2.20) 0.53 (0.22 to 1.26) 1.89 (1.19 to 3.00)** 1.75 (1.16 to 2.65)** 0.78 (0.36 to 1.70) 0.95 (0.43 to 2.09)
  40–54 0.66 (0.28 to 1.52) 1.21 (0.55 to 2.69) 1.27 (0.82 to 1.98) 1.04 (0.70 to 1.54) 0.69 (0.32 to 1.52) 1.11 (0.52 to 2.38)
  55+ 1 1 1 1 1 1
Heaviness of Smoking 
Index
0.99 (0.83 to 1.19) 1.38 (1.10 to 1.72)** 0.96 (0.86 to 1.07) 0.88 (0.79 to 0.97)* 0.85 (0.72 to 1.02) 0.74 (0.61 to 0.90)**
Trigger
  Yes 4.19 (2.33 to 7.53)*** 2.14 (1.07 to 4.29)* 1.45 (1.04 to 2.02)* 1.10 (0.78 to 1.56) 0.99 (0.58 to 1.68) 0.58 (0.28 to 1.20)
  No 1 1 1 1 1 1
Income level
  Low 1.47 (0.70 to 3.08) 1.68 (0.77 to 3.67) 0.76 (0.50 to 1.16) 1.12 (0.78 to 1.61) 0.65 (0.32 to 1.32) 0.45 (0.23 to 0.90)*
  Moderate 0.64 (0.32 to 1.27) 2.00 (0.89 to 4.46) 0.74 (0.50 to 1.09) 0.74 (0.51 to 1.07) 0.62 (0.33 to 1.18) 0.43 (0.21 to 0.88)*
  High 1 1 1 1 1 1
Education level
  Low 2.17 (0.87 to 5.46) 0.49 (0.19 to 1.22) 0.85 (0.52 to 1.38) 0.78 (0.51 to 1.20) 0.70 (0.29 to 1.68) 1.30 (0.56 to 2.98)
  Moderate 0.49 (0.24 to 0.97)* 0.71 (0.32 to 1.56) 0.56 (0.38 to 0.82)** 0.84 (0.59 to 1.21) 0.53 (0.27 to 1.02) 1.11 (0.57 to 2.19)
  High 1 1 1 1 1 1
Time-in-sample 0.85 (0.76 to 0.93) * 0.93 (0.80 to 1.07) 0.96 (0.91 to 1.02) 0.98 (0.91 to 1.05) 1.03 (0.94 to 1.13) 1.12 (0.98 to 1.28) 
*P<0.05; **P<0.01; ***P<0.001. 
†Only participants who made a quit attempt in the last year.
NL, Netherlands; Trigger, participant mentioned free/lower cost medication as a trigger for thinking about quitting smoking.
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a trigger was no longer significantly associated with medication use 
in the NL (OR=1.83, p=0.113), but remained significant in the 
UK (OR=4.26, p<0.001) (results not shown in table).
Quit attempts
A bivariate analysis showed that 36.2% of respondents 
in the NL who mentioned free/lower cost medication as 
a trigger made at least one quit attempt between 2013 and 
2014 compared with 31.5% who did not report this trigger 
(p=0.133, see figure 1). In the UK, these numbers were 48.2% 
vs 39.9% (p=0.025, see figure 2). The multivariate analyses 
showed that in the UK, respondents who mentioned free/
lower cost medication as a trigger had a higher rate of quit 
attempts within the next year than those who did not report 
this trigger (OR=1.45, p=0.030), but this association was 
not found in the NL (OR=1.10, p=0.587, see table 3). There 
were no significant interactions between free/lower cost medi-
cation as a trigger and education and income levels for quit 
attempts in the multivariate analyses. When other policy trig-
gers were added to the analysis as independent variables, free/
lower cost medication as a trigger was no longer significantly 
associated with quit attempts in the UK (OR=1.14, p=0.489), 
and remained non-significant in the NL.
Quit success
Within the group of smokers who made a quit attempt, in the 
NL 19.3% of respondents who mentioned medication as a trigger 
quit smoking successfully compared with 32.0% who did not 
report this trigger (p=0.012, figure 1). In the UK, this was 34.1% 
vs 35.9% (p=0.728, figure 2). The multivariate analyses showed 
no significant association between free/lower cost medication as 
a trigger for thinking about quitting smoking and quit success 
(table 3). The analyses showed no significant interactions between 
free/lower cost medication as a trigger and quit success for different 
income and education levels. With the other three policy triggers 
added to the model, the association between free/lower cost medi-
cation as a trigger and quit success remained not significant.
dIsCussIOn
The aim of this study was to investigate whether mentioning free/
lower cost medication as a trigger to think about quitting smoking 
was related to the use of cessation medication, quit attempts and 
quit success in the UK and the NL, and whether these associations 
were modified by education and income. The results showed a posi-
tive association between mentioning free/lower cost medication 
as a trigger and the use of smoking cessation medication in both 
the UK and the NL. This finding is in line with previous research, 
which showed that financial coverage leads to an increased utilisa-
tion of smoking cessation medication.15
Smokers who mentioned free/lower cost medication as a 
trigger for thinking about quitting smoking were more likely 
to have made a quit attempt a year later in the UK, but not 
in the NL. The association between free/lower cost medica-
tion as a trigger to quit smoking and quit attempts has also 
been demonstrated in Canada, the USA and Australia.18 The 
finding that there was no significant association between 
free/lower cost medication as a trigger and quit attempts in 
the NL may result from the difference in availability of free/
lower cost medication compared with the UK. The UK’s stop-
smoking services and health professionals provide subsidised 
medications for any smokers who want to quit, while in the 
NL health insurance reimbursement for smoking cessation 
medication is only available after a mandatory deductible 
amount is first spent. Not being able to receive free medica-
tion could demotivate smokers to follow through with their 
intended quit attempt.22 32
Smokers who mentioned free/lower cost medication as a trigger 
were not more likely to quit successfully which emphasises that it 
is a large step from contemplating quitting to actually achieving 
this goal. First, there may be barriers preventing smokers to start 
and sustain a quit attempt with medication, such as availability of 
free medication, self-efficacy and motivation.32–35 Likewise, many 
factors can influence whether a quit attempt leads to successful 
quitting.36 The current study did not investigate which hindering 
or promoting factors influence the relation between free/lower 
cost medication as a trigger and quit success, but further research 
focussing on this question could give important insights in how to 
achieve quit success in smokers who are triggered to think about 
quitting by free medication.
When the other policy triggers (smoking restrictions in public 
places, the price of cigarettes and warning labels on cigarette 
packages) were added to the analyses, the associations between 
free/lower cost medication as a trigger and the use of medication 
in the NL, and quit attempts in the UK were no longer signifi-
cant. However, the association between free/lower cost medica-
tion as a trigger and the use of smoking cessation medication in 
the UK remained significant after correcting for the other policy 
triggers, which makes this the most robust finding of this study.
Another aim of this study was to investigate whether the 
income and education level of smokers influenced the associa-
tion between mentioning free/lower cost medication as a trigger 
to quit smoking and use of cessation medications, quit attempts 
and quit success. Contrary to our hypothesis, the results showed 
that this association was not influenced by education or income 
level. This may mean that smokers with a lower SES as well as 
smokers with a higher SES who are triggered to think about quit-
ting smoking by free cessation medication are equally likely to use 
medication, to make a quit attempt and potentially be successful 
in this attempt.
limitations
This study has some limitations that should be taken into 
consideration. The validity of the survey question about 
whether respondents considered free/lower cost medication 
as a trigger to quit smoking was assumed but not investigated 
in this study. Loss to follow-up was higher among younger 
respondents in both countries, which could have influenced 
the results since research has shown that young adults were 
more likely to try quitting smoking, were more successful in 
quitting and were less likely to use cessation medication than 
older adults.37 38 The UK and NL data were not completely 
comparable since there were significant differences in income 
and education levels and differences in measuring the use 
of smoking cessation medication. In the UK, medication use 
was measured for the last quit attempt while in the NL it was 
measured for the last year. Therefore, the use of cessation 
medication may have predated the (by free medication trig-
gered) thought about quitting smoking. In the UK, the lower 
education group was under-represented. In the NL, a large 
portion of the respondents did not disclose their income, which 
could have influenced the results if income was not equally 
distributed among these non-responders. Additionally, in the 
NL, data were collected by web questionnaires only and in the 
UK also by telephone. This difference in data collection could 
have affected survey outcomes but was expected to be of minor 
influence on the results of this study.39
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Practical implications
This study found that smokers who considered free/lower cost 
medication as a trigger to quit smoking were more likely to actu-
ally use cessation medication, and that smokers from the UK 
were more likely to have attempted to quit smoking. To promote 
smoking cessation, it may therefore be beneficial to raise aware-
ness of the availability of free cessation medication, for example, 
through mass media campaigns or healthcare providers.
The finding that the association between mentioning free/
lower cost medication as a trigger for thinking about quitting 
smoking and actual quit attempts was not influenced by educa-
tion or income level suggests that free medication can motivate a 
large part of the smoking population to quit, and that this effect 
is not restricted to particular socioeconomic groups. Yet, since 
free medication is mentioned more often as a trigger to quit 
smoking by lower income smokers in the NL in the current study 
and in previous research also in the UK, Ireland and Germany,17 
free medication may be an important strategy to decrease the 
socioeconomic gap in smoking.
COnClusIOn
Considering free/lower cost smoking cessation medication as a 
trigger for thinking about quitting smoking could, irrespective 
of smokers’ income or education, be positively associated with 
quit attempts and may promote the use of cessation medication 
during this attempt. Therefore, making cessation medication 
freely accessible to smokers may be an important strategy to 
decrease smoking in the population.
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